Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

Biocon Biologics has successfully simplified its capital structure, leading to an upgrade in its ratings by S&P Global. By ...

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan ...

S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process.

On Wednesday, Biocon stock slipped 0.55 per cent to settle at Rs 364.55 apiece on the BSE.

S&P Global Ratings has upgraded Biocon Biologics' long-term issuer credit rating to BB+ from BB, citing a simplified capital structure and improved financial position.

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

This capital raise caps off a year of increasing strategic activity for Biocon. Following shareholder approval on December 31, 2025, the company has ramped up steps to consolidate its biosimilars unit ...

Biocon said the proceeds would be primarily used to meet the cash consideration payable to Mylan Inc, now Viatris, for the acquisition of its shareholding in Biocon Biologics Ltd.

Pharma major Biocon is set to announce its Q3FY26 results on 12 Feb 2026. Brokerage reports project a strong Q3FY26 for ...